Moreover, in breast cancer, PI3K/Akt/mTOR pathway activation is one of the main causes of resistance to antitumor therapies [65] and thus is an important target for improving the sensitivity of tumors to antitumor therapies. This evidence concerns the gene MTOR and breast carcinoma.